Jedidiah I Morton1,2, Jenni Ilomӓki3,4, Dianna J Magliano5,3, Jonathan E Shaw5,3. 1. Baker Heart and Diabetes Institute, Melbourne, VIC, Australia. jedidiah.morton@baker.edu.au. 2. School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia. jedidiah.morton@baker.edu.au. 3. School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia. 4. Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, VIC, Australia. 5. Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.
Abstract
AIMS/HYPOTHESIS: In recent years, several new medications for the treatment of type 2 diabetes have been released and some evidence indicates sociodemographic disparity in their utilisation. We sought to investigate sociodemographic disparities in receipt of diabetes medications across Australia. METHODS: This study included 1,203,317 people with type 2 diabetes registered on the Australian National Diabetes Services Scheme (NDSS) followed from 2007 to 2015. The NDSS was linked to the Australian pharmaceutical claims database. We investigated trends in diabetes medication dispensing and variation in dispensing by sociodemographic strata. RESULTS: Compared with individuals in the least disadvantaged areas, those in the most disadvantaged quintile were less likely to receive dipeptidyl peptidase-4 inhibitors (DPP4is), glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) in the first year of availability (OR [95% CI] for most vs least disadvantaged: 0.78 [0.75, 0.82], 0.65 [0.60, 0.71] and 0.89 [0.84, 0.95], respectively). These disparities dissipated over time for DPP4is and SGLT2is but remained significant for GLP-1RAs. The OR (95% CI) of receiving DPP4is, GLP-1RAs and SGLT2is in the first year of availability for people in remote areas vs major cities was 0.46 (0.39, 0.54), 0.46 (0.35, 0.61) and 0.71 (0.59, 0.84), respectively. These disparities remained significant through to 2015. CONCLUSIONS/ INTERPRETATION: People with diabetes in more disadvantaged areas are less likely to receive newer diabetes medications, although this effect decreased over time. However, there are considerable and persistent differences in receipt of newer diabetes medications between major cities and remote areas of Australia. Graphical abstract.
AIMS/HYPOTHESIS: In recent years, several new medications for the treatment of type 2 diabetes have been released and some evidence indicates sociodemographic disparity in their utilisation. We sought to investigate sociodemographic disparities in receipt of diabetes medications across Australia. METHODS: This study included 1,203,317 people with type 2 diabetes registered on the Australian National Diabetes Services Scheme (NDSS) followed from 2007 to 2015. The NDSS was linked to the Australian pharmaceutical claims database. We investigated trends in diabetes medication dispensing and variation in dispensing by sociodemographic strata. RESULTS: Compared with individuals in the least disadvantaged areas, those in the most disadvantaged quintile were less likely to receive dipeptidyl peptidase-4 inhibitors (DPP4is), glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) in the first year of availability (OR [95% CI] for most vs least disadvantaged: 0.78 [0.75, 0.82], 0.65 [0.60, 0.71] and 0.89 [0.84, 0.95], respectively). These disparities dissipated over time for DPP4is and SGLT2is but remained significant for GLP-1RAs. The OR (95% CI) of receiving DPP4is, GLP-1RAs and SGLT2is in the first year of availability for people in remote areas vs major cities was 0.46 (0.39, 0.54), 0.46 (0.35, 0.61) and 0.71 (0.59, 0.84), respectively. These disparities remained significant through to 2015. CONCLUSIONS/ INTERPRETATION: People with diabetes in more disadvantaged areas are less likely to receive newer diabetes medications, although this effect decreased over time. However, there are considerable and persistent differences in receipt of newer diabetes medications between major cities and remote areas of Australia. Graphical abstract.
Entities:
Keywords:
Australia; DPP4 inhibitors; Diabetes; GLP-1RAs; Health services research; Medications; Pharmacoepidemiology; SGLT2 inhibitors; Socioeconomic status
Authors: Søren L Kristensen; Rasmus Rørth; Pardeep S Jhund; Kieran F Docherty; Naveed Sattar; David Preiss; Lars Køber; Mark C Petrie; John J V McMurray Journal: Lancet Diabetes Endocrinol Date: 2019-08-14 Impact factor: 32.069
Authors: Jetty A Overbeek; Edith M Heintjes; Daniel Prieto-Alhambra; Patrick Blin; Régis Lassalle; Gillian C Hall; Francesco Lapi; Elisa Bianchini; Niklas Hammar; Irene D Bezemer; Ron M C Herings Journal: Clin Ther Date: 2017-03-23 Impact factor: 3.393
Authors: Thomas A Zelniker; Stephen D Wiviott; Itamar Raz; Kyungah Im; Erica L Goodrich; Marc P Bonaca; Ofri Mosenzon; Eri T Kato; Avivit Cahn; Remo H M Furtado; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Marc S Sabatine Journal: Lancet Date: 2018-11-10 Impact factor: 79.321
Authors: Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews Journal: Diabetes Care Date: 2012-04-19 Impact factor: 19.112
Authors: Kasia J Lipska; Xiaoxi Yao; Jeph Herrin; Rozalina G McCoy; Joseph S Ross; Michael A Steinman; Silvio E Inzucchi; Thomas M Gill; Harlan M Krumholz; Nilay D Shah Journal: Diabetes Care Date: 2016-09-22 Impact factor: 19.112
Authors: Alexander C Falkentoft; Julie Andersen; Mariam Elmegaard Malik; Christian Selmer; Peter Haulund Gæde; Peter Bisgaard Staehr; Mark A Hlatky; Emil Fosbøl; Lars Køber; Christian Torp-Pedersen; Gunnar H Gislason; Thomas Alexander Gerds; Morten Schou; Niels E Bruun; Anne-Christine Ruwald Journal: Lancet Reg Health Eur Date: 2022-01-25